Empowering Researchers with Precision: CD Genomics’ Targeted Region Sequencing Service Now Available
CD Genomics, a renowned provider of genomics services, is pleased to announce the launch of its latest offering, Targeted Region Sequencing (TRS).
Uncategorized
Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer
Akebia Therapeutics today announced the appointment of Erik Ostrowski as Senior Vice President, Chief Financial Officer and Chief Business Officer.
Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity
Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity.
MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing
MIRA Pharmaceuticals, Inc. today announced new compelling preclinical results for its investigational compound, Ketamir-2, a novel oral ketamine analog.
Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)
Milestone Phase II Clinical Study Demonstrates Niagen ® , Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD).
QT Imaging Holdings’ Technology Advances Medical Imaging Research at the University of Oklahoma’s Health Stephenson Cancer Center
QT Imaging Holdings, Inc. is honored to partner with University of Oklahoma and OU Health Stephenson Cancer Center to advance and scale innovative research in medical imaging and to improve precision in cancer detection and treatment.
Evommune Secures Exclusive Rights to Develop and Commercialize a Phase 2-ready IL-18 targeted fusion protein from AprilBio
Evommune, Inc. today announced it has entered into a definitive, worldwide license agreement with AprilBio Co., Ltd. (Kosdaq: 397030), a biopharmaceutical company based in South Korea dedicated to developing specialized biologics and antibody drugs, for an IL-18 targeted fusion protein.
Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences, Inc. today announced that it has treated the sixth patient in the ongoing Phase 1 clinical trial.
Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial Read More »
Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration
Silence Therapeutics plc today announced that it will receive a $2.0 million cash payment from Hansoh Pharmaceutical Group Company Limited (“Hansoh”) following the achievement of a second undisclosed milestone related to the first target under the collaboration.
ILiAD Biotechnologies Announces Planned Collaboration with Emmes Group, a New Mountain Capital Portfolio Company, to Conduct Upcoming Phase III Clinical Trials of BPZE1, the Leading Next-Generation Pertussis Vaccine
ILiAD Biotechnologies, LLC today announced the selection of Emmes Group, a global contract research and technology organization, to conduct upcoming Phase III studies of its lead pertussis vaccine candidate, BPZE1. ILiAD and Emmes Group are currently working to finalize the definitive agreement.